Active, not recruitingPhase 2/3
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
Key facts
- Where
- Atlanta, Auburn Hills, Boardman, Boca Raton, Canton, Charleston, Dallas, Douglasville, Encino, Fort Lauderdale, Frisco, Hackensack, Huntington Beach, Las Vegas, Louisville, Mandeville, Margate, Mayfield Heights, Metairie, Mt. Pleasant, New Orleans, North Miami Beach, Northville, Phoenix, Pittsburgh, Plainfield, Prosper, Reno, Santa Monica, Smyrna, Southlake, Spokane, Tampa, The Bronx, and Wildwood, United StatesSee the 35 sites
- Phase
- Phase 2/3
Where in United States
- DelRicht ResearchAtlanta, United StatesNo longer taking part
- Oakland Hills DermatologyAuburn Hills, United StatesNo longer taking part
- Optima Research BoardmanBoardman, United StatesNo longer taking part
- Skin Care ResearchBoca Raton, United StatesNo longer taking part
- Apex Clinical Research Center, LLCCanton, United StatesNo longer taking part
- Medical Univ of SC Department of DermatologyCharleston, United StatesNo longer taking part
- Dermatology Treatment & Research CenterDallas, United StatesNo longer taking part
- Southeast Research Specialist LLCDouglasville, United StatesNo longer taking part
- Encino Research CenterEncino, United StatesNo longer taking part
- Center for Skin Science and InnovationFort Lauderdale, United StatesNo longer taking part
- VAST Clinical Research LLCFrisco, United StatesNo longer taking part
- Schweiger Dermatology, PCHackensack, United StatesNo longer taking part
- Marvel Clinical Research, LLCHuntington Beach, United StatesNo longer taking part
- JDR Dermatology Research, LLCLas Vegas, United StatesNo longer taking part
- DS Research of KentuckyLouisville, United StatesNo longer taking part
- Martha StewartMandeville, United StatesNo longer taking part
- Gsi Clinical ResearchMargate, United StatesNo longer taking part
- Apex Clinical Research Center, LLCMayfield Heights, United StatesNo longer taking part
- Clinical Trials Management, LLCMetairie, United StatesNo longer taking part
- DelRicht ResearchMt. Pleasant, United StatesNo longer taking part
- Delricht ResearchNew Orleans, United StatesNo longer taking part
- Ziaderm Research LLCNorth Miami Beach, United StatesNo longer taking part
- MI Skin InnovationsNorthville, United StatesNo longer taking part
- Saguaro DermatologyPhoenix, United StatesNo longer taking part
- UPMC Department of DermatologyPittsburgh, United StatesNo longer taking part
- The Indiana Clinical Trials Center, PCPlainfield, United StatesNo longer taking part
- DelRicht ResearchProsper, United StatesNo longer taking part
- Skin Cancer and Dermatology InstituteReno, United StatesNo longer taking part
- Clinical Science InstituteSanta Monica, United StatesNo longer taking part
- DelRicht ResearchSmyrna, United StatesNo longer taking part
- Stryde Research-Epiphany DermatologySouthlake, United StatesNo longer taking part
- Dermatology Specialists of SpokaneSpokane, United StatesNo longer taking part
- Clinical Trials Management, LLCTampa, United StatesNo longer taking part
- Equity Medical, LLCThe Bronx, United StatesNo longer taking part
- DelRicht ResearchWildwood, United StatesNo longer taking part
Trial details
- Who runs it
- Bluefin Biomedicine, Inc.
- Trial code
- NCT07287644
- Record updated
- 14 October 2026
- Original description
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.Read full original descriptionShow less
A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Moderate to Severe Hidradenitis Suppurativa
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Inclusion: Are adults (18 to 75 years) with a diagnosis of hidradenitis suppurativa for at least one year; Have moderate to severe disease not well controlled by systemic antibiotic treatment; Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.
Exclusion: Recently used medications that could interfere with the study; Have certain infections or other immune conditions; Are pregnant or breastfeeding.